Get the Daily Brief
Latest Biotech News
Abbott Diagnostics Revenue Dips Amid COVID-19 Test Decline and China VBP Impact
Abbott Laboratories’ second quarter 2025 diagnostics revenue fell 1% year over year to $2.17 billion, pressured by rapid decreases in COVID-19 testing sales and volume-based procurement effects in...
Biotech and Med-Tech Startups Gain Support with Substantial Australian Government Grants
The Australian government awarded nearly AU$100 million (US$64.6 million) in grants to three biopharma and med-tech incubators aimed at fostering emerging startups. These incubators will uplift...
Novartis Names New CFO, Raises Full-Year Sales Guidance
Novartis appointed a new Chief Financial Officer, Mehta, amid ongoing strategic execution and financial management. The Swiss pharmaceutical giant slightly lifted its 2025 full-year sales forecast...
Sarepta gene therapy deaths prompt FDA action and company restructuring
Sarepta Therapeutics is facing significant scrutiny after three patients died following administration of its gene therapies for muscular dystrophies. Two deaths involved Elevidys for Duchenne...
Scipher Medicine pivots to data-driven precision medicine using clinicogenomic datasets
Scipher Medicine is expanding beyond its rheumatoid arthritis molecular diagnostic assay to broader precision medicine efforts in immunology and other non-oncology areas. Under new leadership, the...
FDA advisory committees reject Otsuka's PTSD drug combo and GSK’s Blenrep amid safety concerns
The FDA's advisory committees recently voted negatively on two noteworthy drug candidates. The Psychopharmacologic Drugs Advisory Committee voted 10-1 against Otsuka Pharmaceutical’s combination...
Advancements in biotechnology manufacturing and infrastructure
Significant investments and developments are underway to boost biomanufacturing and life sciences infrastructure globally. GenesisM has commenced construction of a 154,000 square-foot Class A...
Biotechs face funding volatility amid slowing venture capital and public markets
Biotech venture funding slowed significantly in the first half of 2025, with total proceeds dropping to $12.7 billion from $16.9 billion in 2024, underscoring a contraction in capital...
Cutting-edge AI and bioinformatics tools target undruggable proteins and tumor microenvironment
Innovative computational and AI-driven methods are unlocking novel drug discovery pathways. David Baker's lab has engineered AI approaches to design binders targeting intrinsically disordered...
Regulatory and reimbursement challenges impact diagnostic and therapeutic sectors
The FDA and Medicare continue to influence diagnostic test coverage and therapy approvals, shaping market dynamics. Proposed local coverage determinations by Medicare contractor MolDx for...
Notable clinical trial and drug development updates across diverse indications
Recent clinical developments span multiple bioscience areas. Novo Nordisk is preparing Phase 3 trials for an amylin analog and GLP-1 agonist combo targeting weight loss. Diamedica has reported...
Major corporate movements in biotech and med-tech sectors
Strategic leadership changes and corporate consolidations are underway. Novartis named a new CFO, Pranav Mehta, to steer financial strategy amid evolving company goals. Waters Corporation...
Emerging research and technology in neuroscience, immunology, and molecular biology
Cutting-edge studies and innovations shed light on complex biological processes and disease mechanisms. Research explores brain endothelial gap junctions enabling rapid blood flow during neural...
Sarepta’s Gene Therapy Safety Concerns and Major Restructuring
Sarepta Therapeutics faces mounting challenges following the deaths of three patients linked to its gene therapies, notably the Duchenne muscular dystrophy treatment Elevidys and an...
Advances in Three-Person IVF Technology and Mitochondrial Disease Prevention
Recent reports confirm the birth of eight healthy babies in the UK through three-person IVF techniques that replace mitochondrial DNA to prevent transmission of mitochondrial diseases. This...
FDA Advisory Committee Rejects GSK’s Blenrep for Multiple Myeloma
The FDA’s Oncologic Drugs Advisory Committee voted against the approval of GSK’s antibody-drug conjugate Blenrep (belantamab mafodotin) for relapsed/refractory multiple myeloma in combination...
Bristol Myers Squibb’s Reblozyl Fails Phase III Myelofibrosis Anemia Trial
Bristol Myers Squibb's anemia drug Reblozyl missed the primary endpoint in the Phase III INDEPENDENCE trial for myelofibrosis-associated anemia, failing to achieve sustained transfusion...
Life Sciences Venture Financing Trends and Market Analysis
Life sciences sector financing experienced a slowdown in the first half of 2025, with total venture funding decreasing to $12.7 billion from $16.9 billion in 2024, as reported by BioCentury....
Regulatory and Strategic Shifts in Pharma Due to US Tariff Threats and Policies
Pharmaceutical companies are bracing for the impact of potential U.S. drug tariffs anticipated by the end of July under the Trump administration. Despite the uncertainty, Johnson & Johnson CEO...
Innovations in AI for Protein Design and Undruggable Targets
David Baker’s lab at the University of Washington has unveiled AI-driven approaches to design binders targeting intrinsically disordered regions (IDRs) of proteins, overcoming long-standing...